Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

Jürgen K Rockstroh, Sheetal Kassim, Roger Paredes, Christopher Bettacchi, Gary Sinclair, Anchalee Avihingsanon, Nelly Mugo, Jean-Michel Molina, Brenda Crabtree Ramírez, Hiroyuki Gatanaga, Yayun Xu, Stephanie O Klopfer, Tracy L Diamond, Mary Vesnesky, Luisa M Stamm, Michelle C Fox, Mary L Pisculli

Open source

DOI: 10.1016/s2352-3018(26)00033-0
Published: 2026-07
Container: The Lancet HIV
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3018-26-00033-0,
  title = {Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial},
  author = {Jürgen K Rockstroh and Sheetal Kassim and Roger Paredes and Christopher Bettacchi and Gary Sinclair and Anchalee Avihingsanon and Nelly Mugo and Jean-Michel Molina and Brenda Crabtree Ramírez and Hiroyuki Gatanaga and Yayun Xu and Stephanie O Klopfer and Tracy L Diamond and Mary Vesnesky and Luisa M Stamm and Michelle C Fox and Mary L Pisculli},
  year = {2026},
  journal = {The Lancet HIV},
  doi = {10.1016/s2352-3018(26)00033-0},
  url = {https://doi.org/10.1016/s2352-3018(26)00033-0}
}

RIS

TY  - JOUR
TI  - Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
AU  - Jürgen K Rockstroh
AU  - Sheetal Kassim
AU  - Roger Paredes
AU  - Christopher Bettacchi
AU  - Gary Sinclair
AU  - Anchalee Avihingsanon
AU  - Nelly Mugo
AU  - Jean-Michel Molina
AU  - Brenda Crabtree Ramírez
AU  - Hiroyuki Gatanaga
AU  - Yayun Xu
AU  - Stephanie O Klopfer
AU  - Tracy L Diamond
AU  - Mary Vesnesky
AU  - Luisa M Stamm
AU  - Michelle C Fox
AU  - Mary L Pisculli
PY  - 2026
JO  - The Lancet HIV
DO  - 10.1016/s2352-3018(26)00033-0
UR  - https://doi.org/10.1016/s2352-3018(26)00033-0
ER  -

APA

Rockstroh, J. K., Kassim, S., Paredes, R., Bettacchi, C., Sinclair, G., Avihingsanon, A., Mugo, N., Molina, J., Ramírez, B. C., Gatanaga, H., Xu, Y., Klopfer, S. O., Diamond, T. L., Vesnesky, M., Stamm, L. M., Fox, M. C., & Pisculli, M. L. (2026). Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(26)00033-0

Source records

crossref · retrieved 2026-09-27T01:36:30.992Z